Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

A noninvasive algorithm to exclude pre-capillary pulmonary hypertension

D. Bonderman, P. Wexberg, A.M. Martischnig, H. Heinzl, M-B. Lang, R. Sadushi, N. Skoro-Sajer, I.M. Lang
European Respiratory Journal 2011 37: 1096-1103; DOI: 10.1183/09031936.00089610
D. Bonderman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: diana.bonderman@meduniwien.ac.at
P. Wexberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A.M. Martischnig
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. Heinzl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M-B. Lang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Sadushi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. Skoro-Sajer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
I.M. Lang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Current guidelines recommend right heart catheterisation (RHC) in symptomatic patients at risk of pre-capillary pulmonary hypertension (PH) with echocardiographic systolic pulmonary artery pressures ≥36 mmHg. Growing awareness for PH, a high prevalence of post-capillary PH and the inability to distinguish between pre- and post-capillary PH by echocardiography have led to unnecessary RHCs. The aim of our study was to assess whether standard noninvasive diagnostic procedures are able to safely exclude pre-capillary PH.

Data from 251 patients referred for suspicion of pre-capillary PH were used to develop a noninvasive diagnostic decision tree. A prospectively collected data set of 121 consecutive patients was utilised for temporal validation.

According to the decision tree, patients were stratified by the presence or absence of an electrocardiographic right ventricular strain pattern (RVS) and serum N-terminal brain natriuretic peptide (NT-proBNP) levels below and above 80 pg·mL−1. In the absence of RVS and elevated NT-proBNP, none of the patients in the prospective validation cohort were diagnosed with pre-capillary PH by RHC. Combining echocardiography with the diagnostic algorithm increased specificity to 19.3% (p = 0.0009), while sensitivity remained at 100%.

Employing ECG and NT-proBNP on top of echocardiography helps recognise one false positive case per five patients referred with dyspnoea and echocardiographic suspicion of PH, while not missing true pre-capillary PH.

  • Diagnostic procedures
  • pulmonary hypertension

Pre-capillary pulmonary hypertension (PH) is a severe condition leading to right heart failure and death within 2–3 yrs after diagnosis, if left untreated 1. While idiopathic pulmonary arterial hypertension (PAH) is rare, associated forms of PAH 2 are more common and may be triggered by collagen vascular disease, appetite suppressants 3, HIV-infection 4, increased shear stress and hypoxia 2, 5–7. A series of medical conditions, including infection, immune disorders, inflammatory bowel disease and permanent venous catheters 8, 9, predispose to chronic thromboembolic pulmonary hypertension (CTEPH) 10.

According to international guidelines 2, which were recently updated 11–13, invasive haemodynamic measurement by right heart catheterisation (RHC) is recommended in patients with clinical suspicion of pre-capillary PH if systolic pulmonary artery pressure (Ppa,sys) by transthoracic echocardiography (TTE) is ≥36 mmHg. An invasively measured pulmonary capillary wedge pressure of 15 mmHg has been used to discriminate between pre- and post-capillary pulmonary pressure elevation which mostly occurs as a consequence of left-sided heart disease 14. The growing awareness for PH, a high prevalence of post-capillary PH 15 and the inability of TTE to distinguish between pre- and post-capillary PH have necessitated invasive haemodynamic measurements for exclusion. Furthermore, Doppler echocardiography is frequently inaccurate in estimating Ppa,sys 16. Given a low specificity of PH symptoms and Ppa,sys elevations by TTE, the decision to either proceed with RHC or withhold further invasive testing is a common clinical problem, especially in high-volume PH referral centres 17. Although rare 18, complications of RHC may be ventricular tachyarrhythmia, vascular or ventricular perforation, bleeding, pneumothorax and even death 19. However, a restrictive use of RHC may delay a timely diagnosis and treatment 20.

Apart from TTE, 12-lead electrocardiography (ECG), serum N-terminal brain natriuretic peptide (NT-proBNP) and lung function tests with blood gas analysis have been recommended in patients who present with dyspnoea. Typical ECG signs of pre-capillary PH are right ventricular hypertrophy and strain (RVH and RVS, respectively), and signs of right atrial dilation such as P-pulmonale. The role of ECG for the diagnosis of PH has been investigated in a large US registry initiated in the early 1980s. Rich et al. 21 reported that electrocardiographic RVH was present in 87% and right axis deviation in 79% of patients with idiopathic PH. Elevated serum NT-proBNP 22 and hypocapnia 23 have been established as independent markers of mortality in PH. However, the combined diagnostic use of these noninvasive tests has not been validated. Therefore, we tested the ability of standard noninvasive diagnostic procedures to correctly identify or exclude pre-capillary PH in patients referred for clinical suspicion of PH and echocardiographic Ppa,sys ≥36 mmHg. We used a retrospective data set of 251 consecutive individuals and constructed a simple noninvasive diagnostic algorithm. In a prospective temporal validation study enrolling 121 new consecutive patients, the incremental diagnostic value of the combined use of TTE, ECG and NT-proBNP over TTE alone was confirmed.

METHODS

Setting and study design

The study was approved by the Ethics Committee of the Medical University of Vienna (Vienna, Austria), and written informed consent was collected from prospectively enrolled patients. The study was performed at the Pulmonary Hypertension Unit of the Medical University of Vienna as a tertiary referral centre for PH.

Retrospective study

Between January 2002 and April 2007, 462 patients were referred for the evaluation of PH. TTE, 12-lead ECG, serum NT-proBNP and lung function tests including arterial carbon dioxide tension (Pa,CO2) were performed upon admission in each patient. Patients with echocardiographic Ppa,sys <36 mmHg (n = 80) were not considered for invasive haemodynamic assessment. Patients carrying pacemakers or implantable cardioverters/defibrillators (n = 12) were excluded because of the inapplicability of standard ECG criteria. 71 patients were excluded because of severe valvular disease, congenital malformations and/or severely impaired left ventricular function. Of the 299 patients who were considered appropriate study candidates, 48 were excluded because of incomplete data, leaving 251 patients for analysis. Based on the invasive haemodynamic evaluation by RHC, the diagnosis “pre-capillary PH” or “no pre-capillary PH” was made.

Prospective study

For temporal validation of the diagnostic algorithm constructed from the retrospective data set, we enrolled consecutive patients referred between June 2007 and October 2008. From a total of 222 individuals, 101 were excluded because of valvular heart disease (n = 29), left ventricular dysfunction (n = 8), congenital heart disease (n = 8), pacemaker (n = 17) and an echocardiographic Ppa,sys <36 mmHg (n = 30). In one patient NT-proBNP had not been determined and one patient died prior to a complete assessment. Seven patients refused to participate in the study. In the remaining 121 patients, noninvasive diagnostic procedures were performed in an outpatient setting. Based on the diagnostic algorithm, each patient was categorised as “pre-capillary PH excluded” or “pre-capillary PH likely”. In a next step, all patients underwent invasive haemodynamic assessment by RHC. Based on these results, a diagnosis was made that served as the validation standard.

Transthoracic echocardiography

All TTE studies were performed by board certified physicians in the echo laboratory of the Medical University of Vienna using high-end scanners, such as Acuson Sequoia (Siemens AG, Erlangen, Germany) and Vivid 5 and Vivid 7 (General Electric Medical System, Milwaukee, WI, USA). The current standard in our echo lab is that all readings are performed by two independent observers. TTE studies were based on measurements that are broadly available and routinely used in the evaluation of patients with suspected PH.

Right ventricular dysfunction was diagnosed based on a visual assessment and on a tricuspid annular plane systolic excursion of <18 mm. Ppa,sys was calculated by adding estimated right atrial pressure to the tricuspid regurgitation pressure gradient. No contrast agents were used for enhancement of Doppler signals. Right atrial pressure was estimated based on the diameter and respiratory variation of the inferior vena cava 11.

Left ventricular hypertrophy was diagnosed if end-diastolic septal thickness in the apical four-chamber view was ≥12 mm.

Left ventricular diastolic dysfunction was diagnosed in the presence of a restrictive or pseudo-normal filling pattern and normal or only mildly abnormal left ventricular ejection fraction (>50%). A restrictive filling pattern was defined by an E/A waves ratio >2 and a deceleration time <150 ms. A pseudo-normal filling pattern was diagnosed if E/A waves ratio and deceleration time were normal but changed to abnormal after Valsalva 24.

ECG

Retrospective and prospective study

A 12-lead ECG was recorded according to clinical standards at a paper speed of 25 mm·s−1. ECGs were analysed by two cardiologists who were blinded to the clinical and echocardiographic data. ECG rulers and callipers were used. In case of disagreement, consensus was achieved between the two observers in a second reading. The following parameters were obtained: 1) presence or absence of sinus rhythm; 2) heart rate in beats per min; 3) P-wave amplitude in mV in lead II; 4) P-wave axis in degrees; 5) presence or absence of P-pulmonale defined as a P-wave amplitude >0.25 mV; 6) electric heart axis in degrees; 7) right axis deviation defined as a QRS axis >110°; 8) QRS width in ms; 9) presence or absence of bundle branch block defined as a QRS width >100ms, and stratification in right bundle branch block or left bundle branch block; 10) the presence or absence of RVS pattern defined as ST-segment deviation and T-wave inversion in leads V1–V3 25; 11) the presence or absence of left ventricular strain pattern defined as ST-segment deviation and T-wave inversions in leads V5 and V6; 12) QT-length in ms and corrected QT-length calculated by the Bazett formula 26. RVH was defined by a ratio of R and S in lead V1 >1.

Assessments

A detailed medical history including medical conditions known to be associated with PH was obtained 2, 5, 6, 27. Associated conditions were collagen vascular disease, HIV infection, history of appetite suppressant intake, splenectomy or ventriculo-atrial shunt. In addition, exercise capacity measured by the distance in meters walked in 6 min, and the modified New York Heart Association (NYHA) class 28 at presentation were determined in each patient. Blood gas analysis was performed using a ABL 510 blood gas analyser (Radiometer Medical ApS, Brønshøj, Denmark).

Serum NT-proBNP was measured utilising the Elecsys proBNP kit (Roche, Basel, Switzerland). Haemodynamic assessment by RHC included measurement of cardiac output utilising both the Fick equation and the thermodilution method. Pre-capillary PH was diagnosed if mean pulmonary arterial pressure (P̄pa) exceeded 25 mmHg at rest, and pulmonary capillary wedge pressure was <15 mmHg 2.

Statistical analysis

Statistical computations were performed with SPSS (version 15.0; SPSS Inc., Chicago, IL, USA) and SAS (version 9.1; SAS Institute Inc., Cary, NC, USA). Continuous variables were described with mean and sd. Groups were compared using the unpaired t-test. Right-skewed variables were logarithmically transformed before testing. Nominal variables were described with counts and percentages, groups were compared with Chi-squared or Fisher's exact test. Wilson's method was used to compute confidence intervals (CI) for single proportions. McNemar’s test was used to compare sensitivities and specificities of diagnostic decision rules. All reported p-values are the result of two-tailed tests, and p-values <0.05 were considered statistically significant.

Univariable logistic regression models were used to assess whether TTE, clinical and ECG variables allowed discrimination between pre-capillary PH and no pre-capillary PH. Stepwise selection (forward search) within the three groups (TTE, clinical and ECG variables) yielded partially independent variable sets. The clinical and the ECG variable sets were used to construct a diagnostic decision tree (Classification and Regression Tree; CART) for pre-capillary PH versus no pre-capillary PH employing the CHAID (Chi-Squared Automatic Interaction Detection) method of SPSS and defining diagnostic branch points and terminal nodes. At each branch point a case will either branch to the left or to the right based on a test against a threshold predictor value, and will continue branching in subsequent nodes until a terminal node is reached.

Because of the prognostic implications of a delayed PAH diagnosis and treatment 1, a false negative diagnosis was assumed to have far more serious consequences than a false positive one. Therefore, the class assignment rule was chosen in a way that the percentage of false negative predictions did not exceed 4% (one out of 25) of the true positive cases.

To overcome the problem of overoptimistic results, both an internal and a temporal validation step were added 29. Internal validation was based on the bootstrap approach 30, reporting an average of 30 bootstrap samples. Temporal validation was based on the prospective sample.

RESULTS

Characteristics of the retrospective patient cohort

Patient characteristics are summarised in table 1. According to RHC results, 187 (74.5%) patients were classified as pre-capillary PH and 64 (25.5%) as no pre-capillary PH.

View this table:
  • View inline
  • View popup
Table 1– Retrospective clinical, echocardiographic, haemodynamic and electrocardiographic characteristics of patients with pre-capillary pulmonary hypertension (PH) and no pre-capillary PH

In the pre-capillary PH group, 49 patients were eventually diagnosed with idiopathic or familial PH, or PH associated with corrected or small (<2 cm) uncorrected atrial septal defects, two patients had a history of anorexigen intake, six were HIV-positive, 10 female patients suffered from collagen vascular disease, two had PH in association with Osler's disease, 13 patients had underlying lung disease 31, 97 patients had CTEPH, 7 had porto-pulmonary hypertension, and one patient suffered from pulmonary veno-occlusive disease.

In the no pre-capillary PH group, 53 patients were diagnosed with post-capillary PH. Of those, 42 patients suffered from PH due to left ventricular diastolic dysfunction (34 with systemic arterial hypertension and 10 with significant coronary artery disease). Nine patients with post-capillary hypertension suffered from PH due to lung disease and/or hypoxaemia 32. In 11 patients PH was excluded because P̄pa was <25 mmHg. Of those, one patient was diagnosed with pulmonary lymphangioleiomyomatosis, one patient had an isolated pulmonary AV malformation, two patients had manifest hyperthyreoidism, two patients were diagnosed with unilateral pulmonary artery occlusion, two patients had atrial septal defect and three patients had severe isolated tricuspid valve regurgitation.

There were no between-group differences with respect to demographic characteristics, including age and sex. Furthermore, no differences were encountered in the 6-min walking distances or serum creatinine levels. However, statistically significant differences between pre-capillary PH and no pre-capillary PH were found in NYHA class, serum NT-proBNP, Pa,CO2, associated medical conditions, TTE parameters (e.g. Ppa,sys, right ventricular function and diameter, left ventricular wall thickness and diastolic function), haemodynamic parameters, heart rate, and ECG characteristics, e.g. P-wave amplitude and axis, QRS axis, RVH, bundle branch block, RVS pattern and the corrected QT interval (table 1).

Characteristics of the prospective patient cohort

Of 64 (52.9%) patients diagnosed with pre-capillary PH (table 2), 26 had CTEPH, 18 idiopathic or familial PH or PH associated with corrected or small uncorrected atrial septal defect, 13 suffered from PH associated with chronic lung disease 31, three had porto-pulmonary hypertension, two suffered from PH in association with collagen vascular disease and two had PH associated with HIV infection.

View this table:
  • View inline
  • View popup
Table 2– Prospective clinical, echocardiographic, haemodynamic and electrocardiographic characteristics of patients with pre-capillary pulmonary hypertension (PH) and no pre-capillary PH

Of the 57 (47.1%) patients diagnosed with no pre-capillary PH, 32 suffered from post-capillary PH associated with either chronic lung disease 32 or diastolic left ventricular dysfunction, and 25 had normal pulmonary pressures 16. Patients with normal pulmonary pressures suffered from parenchymal or bronchial pulmonary diseases (n = 9), collagen vascular disease (n = 3), coronary artery disease (n = 2), unilateral occlusion of the pulmonary artery (n = 1), isolated tricuspid regurgitation (n = 1), patent arterial duct (n = 1) or abnormal pulmonary vein drainage (n = 1), and seven patients suffered from isolated systemic hypertension.

Predictors of diagnosis

Based on retrospective patient data, univariable (table 3) and three separate multivariable logistic regression models (table 4) were constructed for TTE, clinical parameters and ECG variables. Ppa,sys (OR 1.06, 95% CI 1.03–1.09; p<0.001), right ventricular dysfunction (OR 10.28, 95% CI 2.18–48.44; p = 0.003) and the absence of left ventricular hypertrophy (OR 0.34, 95% CI 0.15–0.75; p = 0.008) were identified as independent predictors of pre-capillary PH. Of the clinical variables tested, serum NT-proBNP (OR 2.01, 95% CI; p = 0.007), Pa,CO2 (OR 0.86, 95% CI 0.79–0.93; p<0.001) and associated medical conditions (OR 3.37, 95%CI 1.04–10.90; p = 0.043) remained independent discriminative factors. ECG variables with the strongest diagnostic accuracy were heart rate (OR 1.05, 95% CI 1.02–1.08; p<0.001) and RVS (OR 52.93, 95% CI 17.27–162.18; p<0.001).

View this table:
  • View inline
  • View popup
Table 3– Clinical, echocardiographic and ECG parameters to predict pre-capillary pulmonary hypertension in the retrospective cohort (univariable logistic regression)
View this table:
  • View inline
  • View popup
Table 4– Clinical, echocardiographic and ECG parameters to predict pre-capillary pulmonary hypertension in the retrospective cohort (multivariable logistic regression)

Accuracy of CART

Because all patients with Ppa,sys ≥36 mmHg and a suspicion of PH were referred for RHC, the sensitivity of TTE was 100% and the specificity was 0.0%. For a more specific noninvasive diagnostic decision tree, all independent clinical and ECG parameters that had been identified in the multivariable logistic regression models (table 4) were fed into the CART algorithm. The model automatically selected RVS and NT-proBNP for primary decision tree construction (fig. 1).

Figure 1–
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1–

Pulmonary hypertension (PH) diagnosis tree based on the Classification and Regression Tree algorithm. Ppa,sys: systolic pulmonary artery pressure; BNP: brain natriuretic peptide; RVS: right ventricular strain.

CART had a sensitivity of 99.4% and a specificity of 40.7%. Because these figures may be too optimistic as they are computed from data the tree had been derived from, two validation steps were added. Internal validation by the bootstrap technique was performed on the original data set resulting in a sensitivity of 97.9% (95% CI 94.5–99.2%) and a specificity of 17.3% (95% CI 9.5–29.5%). Temporal validation was performed on data from 121 prospectively recruited patients and yielded a sensitivity of 100% (95% CI 94.3–100%) and a specificity of 19.3% (95%CI: 11.1–31.3%) (table 5). While sensitivity was unchanged (100% versus 100%; p = 1.0), specificity had improved from 0.0% according to current clinical practice to 19.3% (p = 0.0009).

View this table:
  • View inline
  • View popup
Table 5– Prospective validation of the Classification and Regression Tree algorithm

DISCUSSION

According to current guidelines 2, a significant proportion of patients referred for unexplained dyspnoea are undergoing invasive pressure measurements. To test the accuracy of standard noninvasive diagnostic tools, we analysed data sets from 251 retrospective and 121 prospective patients who underwent RHC for evaluation of PH. The main finding of our study was that ECG and NT-proBNP in addition to TTE suffice to predict significant pre-capillary pulmonary vascular disease at a level of sensitivity of 100% and specificity of 19.3%. In practice, based on the CART algorithm, RHC can be safely withheld in 9% of patients with elevated echo Ppa,sys and clinical PH suspicion without overlooking true PH cases.

PAH, which is one of the major causes of pre-capillary PH, is a severe condition with serious prognosis 33. The availability of potent vasodilator therapies that positively impact on morbidity and mortality 2, 34 has supported early recognition and treatment 20, 35. Moreover, screening of asymptomatic individuals at increased risk for PH has been recommended. While invasive haemodynamic assessment has been considered the diagnostic gold standard in PH, TTE is the recommended screening tool 20, 34. TTE is noninvasive, broadly available and most studies report a high correlation of 0.57–0.93 between TTE and invasive measurements of pulmonary arterial systolic pressures 2. However, elevated Ppa,sys may result from either pre-capillary PH or post-capillary PH, which cannot be safely distinguished by TTE alone. In contrast to post-capillary PH 15, pre-capillary vascular disease is a rare condition 7. These circumstances have recently led to numerous invasive procedures for exclusion. To narrow the grey zone that is blurring the distinction between pre- and post-capillary disease by echocardiography, current recommendations propose an invasive diagnostic work-up in patients with echocardiographic Ppa,sys values >50 mmHg 36. According to our assessments, this diagnostic approach would have substantially increased specificity to 42.1%; however, at the cost of overlooking 6.2% of true pre-capillary PH cases.

Although of limited value, standard ECG has diagnostic 37 and prognostic 38 potential in PH. Despite the fact that post-capillary PH may cause an RVS pattern on ECG 39, RVS remained the strongest predictor of pre-capillary PH in our study. RVS depicts right ventricular electric repolarisation, and appears to be a sensitive and immediate marker of right ventricular strain. The presence of RVS correctly identified 78.8% of pre-capillary PH cases. In addition, several noninvasive prognostic parameters have been established over the years, e.g. the 6-min walk distance 40, NYHA functional class 1, Pa,CO2 23, associated medical conditions 27, 41–43, and serum NT-proBNP levels 44. NT-proBNP is released from both cardiac ventricles in response to increased wall tension and is elevated in PH correlating well with pulmonary vascular resistance 45. Its discriminative accuracy with respect to cardiac versus noncardiac causes of dyspnoea has been described previously 46, and is primarily based upon its excellent negative predictive value of 96% 47. The combination of RVS and NT-proBNP, one being a strong positive, the other a strong negative predictor, confers clinical usefulness.

A main limitation of our study is its single centre design. A centre-specific bias with respect to diagnostic procedures, in particular TTE, cannot be excluded. Different referral patterns may influence proportions of PH versus non-PH cases. However, in contrast to positive and negative predictive values, sensitivities and specificities for the detection of PH are independent of the prevalence of healthy individuals in a given cohort.

Taken together, we would like to emphasise that RHC remains the gold standard for the evaluation of PH 11–13. However, it is widely accepted that a diagnostic procedure that is primarily undertaken to rule out a disease is ideally noninvasive. In a selected patient population referred for dyspnoea and echocardiographic suspicion of PH, integration of the decision tree subsequent to TTE helps to avoid unnecessary RHCs in 9% of cases while not missing a single true PH case.

Footnotes

  • For editorial comments see page 994.

  • Support Statement

    This study received financial support from by the European Commission under the 6th Framework Programme (Contract No LSHM-CT-2005-018725, PULMOTENSION to I.M. Lang). This publication reflects only the author's views and the European Community is in no way liable for any use that may be made of the information contained therein. The research was supported by the Austrian fellowship grant FWFL 513-B11 to D. Bonderman and the Hans und Blanca Moser Stiftung to A.M. Martischnig.

  • Statement of Interest

    None declared.

  • Received June 10, 2010.
  • Accepted July 28, 2010.
  • ©ERS 2011

REFERENCES

  1. ↵
    1. D'Alonzo GE,
    2. Barst RJ,
    3. Ayres SM,
    4. et al
    . Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343–349.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Galie N,
    2. Torbicki A,
    3. Barst R,
    4. et al
    . Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004; 25: 2243–2278.
    OpenUrlFREE Full Text
  3. ↵
    1. Abenhaim L,
    2. Moride Y,
    3. Brenot F,
    4. et al
    . Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 335: 609–616.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Petitpretz P,
    2. Brenot F,
    3. Azarian R,
    4. et al
    . Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. Circulation 1994; 89: 2722–2727.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Bonderman D,
    2. Jakowitsch J,
    3. Adlbrecht C,
    4. et al
    . Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. Thromb Haemost 2005; 93: 512–516.
    OpenUrlPubMedWeb of Science
  6. ↵
    1. Bonderman D,
    2. Wilkens H,
    3. Wakounig S,
    4. et al
    . Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J 2009:33: 325–331.
  7. ↵
    1. Gaine SP,
    2. Rubin LJ
    . Primary pulmonary hypertension. Lancet 1998; 352: 719–725.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Bonderman D,
    2. Jakowitsch J,
    3. Redwan B,
    4. et al
    . Role for staphylococci in misguided thrombus resolution of chronic thromboembolic pulmonary hypertension. Arterioscler Thromb Vasc Biol 2008; 28: 678–684.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Jais X,
    2. Ioos V,
    3. Jardim C,
    4. et al
    . Splenectomy and chronic thromboembolic pulmonary hypertension. Thorax 2005; 60: 1031–1034.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Lang IM
    . Chronic thromboembolic pulmonary hypertension: not so rare after all. N Engl J Med 2004; 350: 2236–2238.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Badesch DB,
    2. Champion HC,
    3. Sanchez MA,
    4. et al
    . Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S55–S66.
    OpenUrlCrossRefPubMedWeb of Science
    1. Galie N,
    2. Hoeper MM,
    3. Humbert M,
    4. et al
    . Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219–1263.
    OpenUrlFREE Full Text
  12. ↵
    1. Galie N,
    2. Hoeper MM,
    3. Humbert M,
    4. et al
    . Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493–2537.
    OpenUrlFREE Full Text
  13. ↵
    1. Hoeper MM,
    2. Barbera JA,
    3. Channick RN,
    4. et al
    . Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S85–S96.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Paulus WJ,
    2. Tschope C,
    3. Sanderson JE,
    4. et al
    . How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28: 2539–2550.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Fisher MR,
    2. Forfia PR,
    3. Chamera E,
    4. et al
    . Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 2009; 179: 615–621.
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Michelakis ED
    . Soluble guanylate cyclase stimulators as a potential therapy for PAH: enthusiasm, pragmatism and concern. Eur Respir J 2009; 33: 717–721.
    OpenUrlFREE Full Text
  17. ↵
    1. Hoeper MM,
    2. Lee SH,
    3. Voswinckel R,
    4. et al
    . Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006; 48: 2546–2552.
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Schenk P,
    2. Stiebellehner L,
    3. Burghuber OC,
    4. et al
    . [Examination of pulmonary circulation using right heart catheterization. Position paper of the Cardiopulmonary Task Force of the Austrian Society for Pneumology and the Austrian Society for Cardiology]. Wien Klin Wochenschr 2005; 117: 651–662.
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. McGoon M,
    2. Gutterman D,
    3. Steen V,
    4. et al
    . Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126: Suppl. 1, 14S–34S.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    1. Rich S,
    2. Dantzker DR,
    3. Ayres SM,
    4. et al
    . Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216–223.
    OpenUrlPubMedWeb of Science
  21. ↵
    1. Fijalkowska A,
    2. Kurzyna M,
    3. Torbicki A,
    4. et al
    . Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006; 129: 1313–1321.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Hoeper MM,
    2. Pletz MW,
    3. Golpon H,
    4. et al
    . Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2007; 29: 944–950.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Dickstein K,
    2. Cohen-Solal A,
    3. Filippatos G,
    4. et al
    . ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388–2442.
    OpenUrlFREE Full Text
  24. ↵
    1. Braunwald E
    . Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 5th Edn. Philadelphia, Elsevier Health, 2004
  25. ↵
    1. Burchell HB
    . The QT interval historically treated. Pediatr Cardiol 1983; 4: 139–148.
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    1. Bonderman D,
    2. Skoro-Sajer N,
    3. Jakowitsch J,
    4. et al
    . Predictors of outcome in chronic thromboembolic pulmonary hypertension. Circulation 2007; 115: 2153–2158.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Hoeper MM,
    2. Oudiz RJ,
    3. Peacock A,
    4. et al
    . End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol 2004; 43: Suppl. 12, 48S–55S.
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    1. Koenig IR,
    2. Malley JD,
    3. Weimar C,
    4. et al
    . Practical experiences on the necessity of external validation. Statist Med 2007; 26: 5499–5511.
    OpenUrlCrossRef
  29. ↵
    1. Efron B,
    2. Tibshirani RJ
    . An Introduction to the Bootstrap. New York, Chapman and Hall, 1993
  30. ↵
    1. Weitzenblum E,
    2. Chaouat A,
    3. Canuet M,
    4. et al
    . Pulmonary hypertension in chronic obstructive pulmonary disease and interstitial lung diseases. Semin Respir Crit Care Med 2009; 30: 458–470.
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    1. Funk GC,
    2. Lang I,
    3. Schenk P,
    4. et al
    . Left ventricular diastolic dysfunction in patients with COPD in the presence and absence of elevated pulmonary arterial pressure. Chest 2008; 133: 1354–1359.
    OpenUrlCrossRefPubMedWeb of Science
  32. ↵
    1. Humbert M,
    2. Sitbon O,
    3. Chaouat A,
    4. et al
    . Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023–1030.
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    1. Grunig E,
    2. Weissmann S,
    3. Ehlken N,
    4. et al
    . Stress Doppler echocardiography in relatives of patients with idiopathic and familial pulmonary arterial hypertension. results of a multicenter European analysis of pulmonary artery pressure response to exercise and hypoxia. Circulation 2009; 119: 1747–1757.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Galie N,
    2. Rubin L,
    3. Hoeper M,
    4. et al
    . Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093–2100.
    OpenUrlCrossRefPubMedWeb of Science
  35. ↵
    1. Olschewski H,
    2. Hoeper MM,
    3. Borst MM,
    4. et al
    . [Diagnosis and therapy of chronic pulmonary hypertension]. Pneumologie 2006; 60: 749–771.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Ahearn GS,
    2. Tapson VF,
    3. Rebeiz A,
    4. et al
    . Electrocardiography to define clinical status in primary pulmonary hypertension and pulmonary arterial hypertension secondary to collagen vascular disease. Chest 2002; 122: 524–527.
    OpenUrlCrossRefPubMedWeb of Science
  37. ↵
    1. Bossone E,
    2. Paciocco G,
    3. Iarussi D,
    4. et al
    . The prognostic role of the ECG in primary pulmonary hypertension. Chest 2002; 121: 513–518.
    OpenUrlCrossRefPubMedWeb of Science
  38. ↵
    1. Enomoto H
    . Clinical studies on the ventricular strain pattern electrocardioogram (I) : clinical statistical studies. Jap Circ J 1961; 25: 1277–1286.
    OpenUrlPubMed
  39. ↵
    1. Miyamoto S,
    2. Nagaya N,
    3. Satoh T,
    4. et al
    . Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000; 161: 487–492.
    OpenUrlCrossRefPubMedWeb of Science
  40. ↵
    1. Kawut SM,
    2. Taichman DB,
    3. Archer-Chicko CL,
    4. et al
    . Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003; 123: 344–350.
    OpenUrlCrossRefPubMedWeb of Science
    1. Kawut SM,
    2. Taichman DB,
    3. Ahya VN,
    4. et al
    . Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl 2005; 11: 1107–1111.
    OpenUrlCrossRefPubMedWeb of Science
  41. ↵
    1. Rich S,
    2. Shillington A,
    3. McLaughlin V
    . Comparison of survival in patients with pulmonary hypertension associated with fenfluramine to patients with primary pulmonary hypertension. Am J Cardiol 2003; 92: 1366–1368.
    OpenUrlCrossRefPubMedWeb of Science
  42. ↵
    1. Nagaya N,
    2. Nishikimi T,
    3. Uematsu M,
    4. et al
    . Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102: 865–870.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Pruszczyk P
    . N-terminal pro-brain natriuretic peptide as an indicator of right ventricular dysfunction. J Card Fail 2005; 11: Suppl. 5, S65–S69.
    OpenUrlCrossRefPubMedWeb of Science
  44. ↵
    1. Tabbibizar R,
    2. Maisel A
    . The impact of B-type natriuretic peptide levels on the diagnoses and management of congestive heart failure. Curr Opin Cardiol 2002; 17: 340–345.
    OpenUrlCrossRefPubMedWeb of Science
  45. ↵
    1. Maisel AS,
    2. Krishnaswamy P,
    3. Nowak RM,
    4. et al
    . Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161–167.
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 37 Issue 5 Table of Contents
European Respiratory Journal: 37 (5)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A noninvasive algorithm to exclude pre-capillary pulmonary hypertension
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
A noninvasive algorithm to exclude pre-capillary pulmonary hypertension
D. Bonderman, P. Wexberg, A.M. Martischnig, H. Heinzl, M-B. Lang, R. Sadushi, N. Skoro-Sajer, I.M. Lang
European Respiratory Journal May 2011, 37 (5) 1096-1103; DOI: 10.1183/09031936.00089610

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
A noninvasive algorithm to exclude pre-capillary pulmonary hypertension
D. Bonderman, P. Wexberg, A.M. Martischnig, H. Heinzl, M-B. Lang, R. Sadushi, N. Skoro-Sajer, I.M. Lang
European Respiratory Journal May 2011, 37 (5) 1096-1103; DOI: 10.1183/09031936.00089610
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Pulmonary vascular disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original Article

  • Lung volumes and survival in chronic lung allograft dysfunction
  • Social consequences of sleep disordered breathing
  • Diagnosing airflow obstruction in COPD
Show more Original Article

Pulmonary Vascular Disease

  • Cytokines as prognostic biomarkers in PAH
  • COVID-19 and case fatality in pulmonary embolism
  • PULSAR: sotatercept for the treatment of PAH
Show more Pulmonary Vascular Disease

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society